Yang JC, Ohe Y, Chiu CH, Ou X, et al. Osimertinib plus selumetinib in EGFR-mutated, non-small cell lung cancer after progression on EGFR-TKIs: A Phase 1b, open-label, multicenter trial (TATTON Part B). Clin Cancer Res 2022 May 26. pii: 699247. doi: 10.1158/1078-0432.CCR-21-4329.
PMID: 35617514